MedTrace Logo

Acceptance and Commitment Therapy (ACT-HBC) for the Improvement of Cancer Distress in Patients With Hepatobiliary Cancers

NCT07124546 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-08-15

No results posted yet for this study

Summary

This clinical trial studies whether Acceptance and Commitment Therapy for patients with hepatobiliary cancers (ACT-HBC) can be used to help improve cancer distress. Patients with hepatobiliary cancer (HBC) often experience high levels of distress and reductions in quality of life. ACT-HBC is a behavioral intervention tailored to patients with HBC. It helps patients cope with difficult thoughts and emotions while staying connected to what matters most in life, which may be an effective way to improve cancer distress.

Conditions

  • Malignant Hepatobiliary Neoplasm

Interventions

BEHAVIORAL

Acceptance and Commitment Therapy

Attend ACT-HBC telehealth group sessions

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Telemedicine

Attend ACT-HBC telehealth group sessions

Sponsors & Collaborators

Principal Investigators

  • Carrie A Bronars, PhD, LP · Mayo Clinic in Rochester

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-28
Primary Completion
2027-05-30
Completion
2027-05-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07124546 on ClinicalTrials.gov